Richard Rogers, Ph.D.Principal Scientist at Bristol Myers Squibb, USA
Dr. Rogers got his Ph.D. from the Johns Hopkins University in 2003. In Mike Matunis’ lab he studied the effects of Sumo modification on transcription factors. As a post doc, Dr. Rogers joined John Aitchison’s lab at the Institute for Systems Biology. At the ISB, Dr. Rogers expanded his research on post translational modification by applying mass spectrometry to detect phosphoryatlation and other ubiquitin-like modifications in macrophages. In 2012, Dr. Rogers joined the Analytical Sciences group at Amgen. At Amgen, Dr. Rogers developed a mass spectrometry based multi-attribute method (MAM) for biotherapeutic characterization and release from QC. Dr. Rogers is currently working for Just Biotherapeutics in Seattle. At Just, Dr. Rogers is continuing his work on the MAM.